In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Consultation end date

Type

Showing 11 to 17 of 17

TitleConsultationTypeConsultation end date
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]Draft guidanceTechnology appraisal guidance
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]Draft guidanceTechnology appraisal guidance
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Draft guidanceTechnology appraisal guidance
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]Draft guidanceTechnology appraisal guidance
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]Draft guidanceTechnology appraisal guidance
Cardiovascular risk assessment and lipid modificationQuality standard consultationQuality standard
Sparsentan for treating primary IgA nephropathy [ID6308]Draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All